Register for our free email digests:
Division of Royal Philips Electronics NV
Latest From BioMarin Pharmaceutical Inc.
Kala follows July's first biopharma IPO from Ionis spinout Akcea into the stock market. Amicus, Arena and othera go high with major offerings, while Inovio and Regulus go low. Also, Galena, Neothetics provide updates on their hunts for "strategic alternatives."
A legal settlement with BioMarin means that Sarepta doesn't have to worry anymore about the potential to infringe patents related to exon-skipping DMD therapies. Meanwhile, BioMarin gains some compensation for its ill-fated Prosensa buy.
IPOs are up, hemophilia is driving company pipelines, speculation over Pascal Soriot's career plans drive billions from AstraZeneca's market capitalization, Sanofi signs a $650m vaccine deal, private equity bidders up their offer for Stada and earnings season kicks off. Commercial capsule rounds up recent business news and trends reported by sister publication Scrip.
Pipeline Watch: Phase III Starts With Fitusiran In Hemophilia, Zoliflodacin In Gonorrhea, Opdivo Combo In RCC
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Diagnostic Imaging Equipment & Supplies
- MRI, NMR
- Monitoring Equipment & Devices
- Diagnostic Imaging Equipment & Supplies
- Therapeutic Areas
- Philips Medical Systems Inc.
- North America
- Parent & Subsidiaries
- Royal Philips Electronics NV
- Senior Management
Deborah DiSanzo, EVP, CEO
Abhijit Bhattacharya, EVP, CFO
- Contact Info
Phone: (978) 659-3000
3000 Minuteman Rd.
Andover, MA 01810-1099
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.